| Literature DB >> 31736878 |
Yanting Wu1,2, Mei Han1,3, Yan Wang1, Yao Gao4, Xianwei Cui1, Pengfei Xu1, Chenbo Ji1, Tianying Zhong3, Lianghui You1, Yu Zeng3.
Abstract
As an important secretory organ, skeletal muscle has drawn attention as a potential target tissue for type 2 diabetic mellitus (T2DM). Recent peptidomics approaches have been applied to identify secreted peptides with potential bioactive. However, comprehensive analysis of the secreted peptides from skeletal muscle tissues of db/dbEntities:
Keywords: Irs1-Akt signaling pathway; Pgc1α; insulin resistance; mass spectrometry; secreted peptide; skeletal muscle
Year: 2019 PMID: 31736878 PMCID: PMC6828820 DOI: 10.3389/fendo.2019.00741
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Differentially secreted peptides from the cultured skeletal muscle tissues from db/db and Control mice. (A) Heatmaps highlight the peptides intensity patterns differentially secreted from the medium supernatants of cultured skeletal muscle tissues from control (con) vs. db/db (db) groups, n = 4 per group. (B) Volcano plot after two-sample t test for peptides detected in medium supernatants derived from the cultured skeletal muscle from control and db/db mice. Red color indicates peptides we defined as up-regulated peptides and blue indicates down-regulated peptides.
Differentially expressed peptides secreted from the medium supernatants of cultured skeletal muscle tissues from db/db and control mice.
| AVGAVFDISNADRLGSSEVEQ | P07310 | KCRM | 2163 | 9.728 | 0.005 |
| TNGAFTGEISPGMIKDLGATWV | P17751 | TPIS | 2264 | 8.019 | 0.035 |
| IADLVVGLCTGQIK | P21550 | ENOB | 1486 | 6.77 | 0.000 |
| NYKPQEEYPDLSKHNNHMA | P07310 | KCRM | 2315 | 4.843 | 0.024 |
| EEIEEDAGLGNGGLGRLAAC | Q9WUB3 | PYGM | 2030 | 4.411 | 0.004 |
| GQCGDVLRALGQNPTQAEV | P09542 | MYL3 | 2013 | 4.077 | 0.033 |
| AGPLCLQEVDEPPQHAL | P70296 | PEBP1 | 1873 | 4.038 | 0.004 |
| EAFTVIDQNRDGIID | P97457 | MLRS | 1705 | 3.947 | 0.026 |
| DLFDPIIQDRHGGY | P07310 | KCRM | 1645 | 3.668 | 0.022 |
| KDLFDPIIQD | P07310 | KCRM | 1203 | 3.282 | 0.000 |
| LDDVIQTGVDNPGHP | P07310 | KCRM | 1576 | 3.265 | 0.001 |
| SEIIDVSSKAEEVK | A2ASS6 | TITIN | 1533 | 3.134 | 0.002 |
| VIACIGEKLDE | P17751 | TPIS | 1246 | 2.976 | 0.003 |
| GTNPTNAEVKKVLGNPSNEEM | Q545G5 | MYL1 | 2180 | 2.838 | 0.006 |
| ADRLGSSEVEQVQLV | P07310 | KCRM | 1629 | 2.804 | 0.001 |
| IGQGTPIPDLPEVKRV | A2AQA9 | NEB | 1719 | 2.739 | 0.002 |
| STTAPPIQSPLPVIPHQK | E9PYJ9 | LDB3 | 1910 | 2.685 | 0.023 |
| KADDGRPFPQVI | P05064 | ALDOA | 1342 | 2.644 | 0.021 |
| KSMTEQEQQQLIDD | P07310 | KCRM | 1692 | 2.442 | 0.001 |
| GGGASLELLEGKVLPGVDA | P09411 | PGK1 | 1781 | 2.264 | 0.028 |
| LEGTLLKPNMVTPGHA | P05064 | ALDOA | 1677 | 2.208 | 0.010 |
| VMVGMGQKDSYVGDEAQSK | P68134 | ACTS | 2028 | 2.168 | 0.021 |
| DLEEATLQHEATAAALR | Q02566 | MYH6 | 1838 | 2.07 | 0.038 |
| AELQEVQITEEKPLLPG | Q9QYG0 | NDRG2 | 1935 | 2.043 | 0.048 |
| SEGKCAELEEELKTVTNNL | P58771 | TPM1 | 2163 | 2.038 | 0.049 |
| RSIKGYTLPPHC | P07310 | KCRM | 1428 | 1.967 | 0.001 |
| NSNSHSSTFDAGAGIALNDNFVK | P16858 | G3P | 2365 | 1.935 | 0.038 |
| TGKATSEASVSTPEETAPEPAKVPT | P70402 | MYBPH | 2484 | 1.919 | 0.003 |
| DNEYGYSNRVVDL | P16858 | G3P | 1543 | 1.898 | 0.004 |
| EELDAMMKEASGPINF | P97457 | MLRS | 1781 | 1.853 | 0.012 |
| SNNKDQGGYEDFVEGLRV | Q545G5 | MYL1 | 2026 | 1.816 | 0.016 |
| AEQIKHILANF | P63028 | TCTP | 1283 | 1.787 | 0.044 |
| GADPEDVITGAFK | P97457 | MLRS | 1319 | 1.782 | 0.031 |
| TSIEDAPITVQSKINQ | A2AQA9 | NEB | 1743 | 1.739 | 0.028 |
| LKGGDDLDPNYVLS | P07310 | KCRM | 1505 | 1.732 | 0.040 |
| IQTGVDNPGHPF | Q6P8J7 | KCRS | 1281 | 1.600 | 0.045 |
| AEVKKVLGNPSNEEMNAK | Q545G5 | MYL1 | 1957 | 1.595 | 0.009 |
| GQEQWEEGDLYDKEKQQKPF | E9Q8K5 | TITIN | 2481 | 1.586 | 0.036 |
| AGTNGETTTQGLDGLSERCA | P05064 | ALDOA | 2037 | 1.582 | 0.033 |
| RVPTPNVSVVDLTCRLEKPAK | P16858 | G3P | 2378 | 1.531 | 0.022 |
| KVPEKPEVVEKVEPAPLK | F7CR78 | F7CR78 | 2015 | 1.527 | 0.026 |
| GETTTQGLDGLSERCAQ | P05064 | ALDOA | 1822 | 1.526 | 0.042 |
| KIEFTPEQIEEF | P09542 | MYL3 | 1509 | 0.612 | 0.021 |
| DLSAIKIEFSKEQQEDF | P05977 | MYL1 | 2026 | 0.600 | 0.019 |
| HELYPIAKGDNQSPI | P16015 | CAH3 | 1681 | 0.559 | 0.038 |
| NSLTGEFKGKY | P07310 | KCRM | 1243 | 0.545 | 0.027 |
| DEPKPYPYPNLDDF | Q3V1D3 | AMPD1 | 1709 | 0.543 | 0.034 |
| ASHHPADFTPAVHA | Q91VB8 | HBA-A1 | 1457 | 0.537 | 0.016 |
| SQVGDVLRALGTNPTNAE | Q545G5 | MYL1 | 1841 | 0.516 | 0.047 |
| ADEIAKAQVAQPGGDTI | P70349 | HINT1 | 1725 | 0.515 | 0.038 |
| DKETPSGFTLDDV | P07310 | KCRM | 1423 | 0.478 | 0.037 |
| LGTNPTNAEVKKVLGNPSNEEMNAK | Q545G5 | MYL1 | 2654 | 0.467 | 0.038 |
| PHPYPALTPEQKK | P05064 | ALDOA | 1505 | 0.407 | 0.028 |
| QLVVDGVKLM | P07310 | KCRM | 1101 | 0.400 | 0.001 |
| KDLFDPIIQDRHG | P07310 | KCRM | 1553 | 0.395 | 0.022 |
| KGVVPLAGTNGETTTQGLDGLSER | P05064 | ALDOA | 2399 | 0.367 | 0.015 |
| RVFDKEGNGTVMGAELR | Q545G5 | MYL1 | 1878 | 0.341 | 0.043 |
| NADEVGGEALGRL | A8DUK4 | HBB-BS | 1300 | 0.339 | 0.037 |
| NEHLGYVLTCPS | P07310 | KCRM | 1389 | 0.328 | 0.031 |
| ASHTEEEVSVSVPEVQKKTVTEEK | E9Q8K5 | TITIN | 2669 | 0.253 | 0.023 |
| NEEDHLRV | P07310 | KCRM | 1010 | 0.212 | 0.027 |
| VLTCPSNLGTGLRG | P07310 | KCRM | 1444 | 0.201 | 0.018 |
| GGYKPTDKHKTDL | P07310 | KCRM | 1459 | 0.127 | 0.006 |
Figure 2Charactrization of the basic feature of differentially secreted peptides. (A) Histogram displaying the Mr distribution of differentially secreted peptides from skeletal muscle peptidomics. (B) Histogram displaying the pI distribution of differentially secreted peptides from skeletal muscle peptidomics. (C) Scatter plot of Mr vs. pI.
Figure 3Comprehensive location and functional assessment of precursor proteins of these differential peptides. (A) GO analysis of precursor proteins and TOP 20 GO terms in the biological process categories. (B) Canonical pathways analysis of precursor proteins and TOP 14 pathways terms in the biological process categories. (C) Distribution of intercellular location of precursor proteins. (D) Search tool for the retrieval of interacting genes/proteins (STRING) was used to construct a graphical network for describing the interaction between these precursor proteins corresponding to the identified peptides. The size of node represents the number of interacting proteins and the color of node represents the bitscore of matching results from STRING database. The thicker the line (edge), the higher the reliability (evaluated by combined score >0.4).
Figure 4Analysis of cleavage pattern of differentially secreted peptides. (A) Distribution of the four cleavage sites in the identified differentially secreted peptides. (B) Peptides derived from the same precursor protein KCRM or ALDOA.
Differentially secreted peptides located in functional domain or region based on Uniprot or Pfam database.
| AVGAVFDISNADRLGSSEVEQ | KCRM | 329–349 | 125–367 | Phosphagen kinase C-terminal |
| TNGAFTGEISPGMIKDLGATWV | TPIS | 121–142 | 57–295 | TIM |
| IADLVVGLCTGQIK | ENOB | 381–394 | 142–432 | Enolase C |
| NYKPQEEYPDLSKHNNHMA | KCRM | 13–31 | 11–98 | Phosphagen kinase N-terminal |
| EEIEEDAGLGNGGLGRLAAC | PYGM | 124–143 | 113–828 | Phosphorylase |
| GQCGDVLRALGQNPTQAEV | MYL3 | 83–101 | 58–95 | EF-hand 1 |
| EAFTVIDQNRDGIID | MLRS | 32–46 | 25–60 | EF-hand 1 |
| DLFDPIIQDRHGGY | KCRM | 87–100 | 11–98 | Phosphagen kinase N-terminal |
| KDLFDPIIQD | KCRM | 86–95 | 11–98 | Phosphagen kinase N-terminal |
| LDDVIQTGVDNPGHP | KCRM | 53–67 | 11–98 | Phosphagen kinase N-terminal |
| VIACIGEKLDE | TPIS | 174–184 | 57–295 | TIM |
| GTNPTNAEVKKVLGNPSNEEM | MYL1 | 39–59 | 6–41 | EF-hand |
| ADRLGSSEVEQVQLV | KCRM | 339–353 | 125–367 | Phosphagen kinase C-terminal |
| KADDGRPFPQVI | ALDOA | 87–98 | 15–364 | Glycolytic |
| KSMTEQEQQQLIDD | KCRM | 177–190 | 125–367 | Phosphagen kinase C-terminal |
| GGGASLELLEGKVLPGVDA | PGK1 | 395–413 | 9–406 | PGK |
| LEGTLLKPNMVTPGHA | ALDOA | 224–239 | 15–364 | Glycolytic |
| VMVGMGQKDSYVGDEAQSK | ACTS | 45–63 | 4–377 | Actin |
| DLEEATLQHEATAAALR | MYH6 | 1,179–1,195 | 845–1,926 | Myosin_tail_1 |
| SEGKCAELEEELKTVTNNL | TPM1 | 186–204 | 1–284 | Coiled coili |
| RSIKGYTLPPHC | KCRM | 135–146 | 125–367 | Phosphagen kinase C-terminal |
| SNNKDQGGYEDFVEGLRV | MYL1 | 77–94 | 83–118 | EF-hand |
| AEQIKHILANF | TCTP | 119–129 | 1–172 | TCTP |
| GADPEDVITGAFK | MLRS | 93–105 | 95–130 | EF-hand 2 |
| LKGGDDLDPNYVLS | KCRM | 115–128 | 125–367 | Phosphagen kinase C-terminal |
| GQEQWEEGDLYDKEKQQKPF | TITIN | 1,691–1,710 | 1,709–1,799 | Ig-like |
| AGTNGETTTQGLDGLSERCA | ALDOA | 117–136 | 15–364 | Glycolytic |
| RVPTPNVSVVDLTCRLEKPAK | GAPDH | 232–252 | 243–248 | [IL]-x-C-x-x-[DE] motif |
| GETTTQGLDGLSERCAQ | ALDOA | 121–137 | 15–364 | Glycolytic |
| KIEFTPEQIEEF | MYL3 | 52–63 | 58–95 | EF-hand 1 |
| DLSAIKIEFSKEQQEDF | MYL1 | 33–49 | 44–79 | EF-hand 1 |
| HELYPIAKGDNQSPI | CAH3 | 17–31 | 3–259 | Alpha-carbonic anhydrase |
| NSLTGEFKGKY | KCRM | 163–173 | 125–367 | Phosphagen kinase C-terminal |
| ASHHPADFTPAVHA | HBA-A1 | 111–124 | 3–142 | GLOBIN |
| DKETPSGFTLDDV | KCRM | 44–56 | 11–98 | Phosphagen kinase N-terminal |
| LGTNPTNAEVKKVLGNPSNEEMNAK | MYL1 | 76–100 | 83–118 | EF-hand |
| QLVVDGVKLM | KCRM | 351–360 | 125–367 | Phosphagen kinase C-terminal |
| KDLFDPIIQDRHG | KCRM | 86–98 | 11–98 | Phosphagen kinase N-terminal |
| KGVVPLAGTNGETTTQGLDGLSER | ALDOA | 111–134 | 15–364 | Glycolytic |
| RVFDKEGNGTVMGAELR | MYL1 | 147–163 | 133–150 | EF-hand |
| NADEVGGEALGRL | HBB-BS | 20–32 | 2–147 | GLOBIN |
| NEHLGYVLTCPS | KCRM | 274–285 | 125–367 | Phosphagen kinase C-terminal |
| NEEDHLRV | KCRM | 230–237 | 125–367 | Phosphagen kinase C-terminal |
| VLTCPSNLGTGLRG | KCRM | 280–293 | 125–367 | Phosphagen kinase C-terminal |
Protein precursors of peptides which are both associated with obesity and diabtetes (Score >0).
| TPI1 | Triosephosphate isomerase | 2 | 0.012 | 0.012 |
| KCRM | Creatine kinase M-type | 17 | 0.022 | 0.017 |
| TTN | Titin | 1 | 0.026 | 0.063 |
| GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | 1 | 0.071 | 0.117 |
| HBA-A1 | Alpha globin 1 | 1 | 0.014 | 0.038 |
| ENOB | Beta-enolase | 1 | 0.040 | 0.048 |
| CAH3 | Carbonic anhydrase 3 | 1 | 0.074 | 0.094 |
| TCTP | Translationally-controlled tumor protein | 1 | 0.028 | 0.040 |
| HBB-BS | Beta-globin | 1 | 0.008 | 0.020 |
| ACTS | Actin, alpha skeletal muscle | 1 | 0.006 | 0.188 |
The association score come from open targets platform database.
Figure 5Effect of the candidate peptides on insulin and mitochondrial-related pathways. The differentiated C2C12 motes were treated with the candidate peptides (50 uM) named P1–P7 groups or solvent termed untreated groups. After incubation with or without 100 nM insulin for 30 min, cell lysates were analyzed by Western blot. (A,C) Total protein and phosphorylation of Irs1 at ser307 (p-Irs1) and Akt at ser473 (p-Akt). (B,D) Quantification of the protein levels of p-Irs1 (ser307) and p-Akt (ser473) relative to total protein, respectively. (E) Mitochondrial-related protein Pgc1α was detected and Tublin was used as internal control. (F) Quantification of the protein levels of Pgc1α relative to Tublin. Values are the means ± SD of three separate experiments. (G,H) Real-time quantitative PCR detection of the mRNA levels of Glut4 and Pgc1 relative to internal control PPIA, respectively. Values are the means ± SD of three separate experiments. *P < 0.05; **P < 0.01; ***P < 0.001.